Tofersen therefore is being evaluated in presymptomatic ALS patients with SOD1 mutations, with the expectation that a wider therapeutic window will give more of an opportunity for reductions in NfL, presumably reflecting slower rates of neurodegeneration that translate to functional patient outcomes. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.